×

product

Pasireotide (SOM230) – Multi-Receptor Somatostatin Analogue

  • Assay:98%
  • CAS: 396091-73-9
  • Molecular formula: C58H66N10O9
  • Molecular weight: 1047.21 g/mol

    We are one of the few specialized suppliers offering Pasireotide (SOM230), the next-generation cyclohexapeptide somatostatin analogue. Unlike first-generation analogues (Octreotide/Lanreotide) that primarily target the sst2 receptor, Pasireotide is engineered to exhibit a broad binding profile, showing high affinity for sst1, sst2, sst3, and sst5. We provide this complex, high-value API to advanced research institutions and pharmaceutical companies investigating Cushing’s disease and refractory neuroendocrine tumors.

    Our Quality Control Standards

    At Saien, we maintain strict quality control standards to ensure that our products meets the highest quality and safety requirements.

    Purity and Potency:Each batch is thoroughly tested to ensure it meets the required purity (typically 98% or higher).

    Heavy Metal Testing:We conduct comprehensive testing for heavy metals such as lead, mercury, arsenic, and cadmium, ensuring compliance with international safety limits.

    Microbial Control:All batches are tested for microbial limits (including bacteria, yeast, and mold) to guarantee safety.

    Moisture Content:We monitor and control moisture content to remain below 5% to prevent degradation.

    Solubility:We conduct solubility tests to confirm effective dissolution in formulations.

    Stability Testing:We perform stability studies to ensure quality is maintained under various environmental conditions.

    Identity Testing:Advanced identification testing (HPLC, UV spectroscopy) ensures the integrity of the product.

    Related Products

    View All